Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Breaking Updates in Hematological-Oncology
The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.ASH 2021
;
At #ASH23, @Eddie_Cliff (@BrighamWomens) shared insights from the POLARIX trial, revealing differences in the efficacy of R-CHP between subgroups of patients with #DLBCL.
Watch here:
👉
#Lymphoma #LYsm #TrialUpdate #CTSM #HemOnc @ASH_Hematology
POLARIX: R-CHP is more effective in the subgroup of DLBCL patients with activated B-cell origin
Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, speaks on the POLARIX trial (NCT03274492), focusi...
ow.ly
Please spread the message and book your calendar
@COMyCongress @TheIACH
Want to hear about the highlights in the field of CLL from #ASH23, with a focus on the FLAIR study?
Then check out our interview with @DrMDavids of @DanaFarber here:
👉
#CLLsm #LeuSM #Leukemia #CTSM #HemOnc #ASH23 @ASH_hematology
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the highlights in the space of chronic lym...
ow.ly
🎥 @thomas_cluzeau of @CHUdeNice talks on the preliminary results of the VENTOGRAPH trial of AZA, VEN, and DLI in MDS and AML following AHSCT relapse.
Watch here:
👉
#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc #ASH23 @ASH_hematology
VENTOGRAPH trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following AHSCT
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the preliminary findings of the ...
ow.ly
Prof. John Gribben (@QMBCI) gave a wonderful insight into axi-cel in R/R #FollicularLymphoma at #ASH23 with an updated comparison of ZUMA-5 and SCHOLAR-5.
Watch here:
👉
#LYMsm #Lymphoma #NonHodgkinLymphoma #ImmunoOnc #HemOnc @ASH_hematology
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, comments on the updated 4-year ...
ow.ly
ASH 2021
Breaking Updates in Hematological-Oncology
The American Society of Hematology (ASH) 2021 Annual Meeting and Exposition was held in Atlanta on the 11-14 December. ASH has successfully honed the hybrid model and showcased outstanding leaps in understanding and treatment in 2021, across malignancies. Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.At #ASH23, @Eddie_Cliff (@BrighamWomens) shared insights from the POLARIX trial, revealing differences in the efficacy of R-CHP between subgroups of patients with #DLBCL.
Watch here:
👉
#Lymphoma #LYsm #TrialUpdate #CTSM #HemOnc @ASH_Hematology
POLARIX: R-CHP is more effective in the subgroup of DLBCL patients with activated B-cell origin
Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, speaks on the POLARIX trial (NCT03274492), focusi...
ow.ly
Please spread the message and book your calendar
@COMyCongress @TheIACH
Want to hear about the highlights in the field of CLL from #ASH23, with a focus on the FLAIR study?
Then check out our interview with @DrMDavids of @DanaFarber here:
👉
#CLLsm #LeuSM #Leukemia #CTSM #HemOnc #ASH23 @ASH_hematology
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the highlights in the space of chronic lym...
ow.ly
🎥 @thomas_cluzeau of @CHUdeNice talks on the preliminary results of the VENTOGRAPH trial of AZA, VEN, and DLI in MDS and AML following AHSCT relapse.
Watch here:
👉
#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc #ASH23 @ASH_hematology
VENTOGRAPH trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following AHSCT
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the preliminary findings of the ...
ow.ly
Prof. John Gribben (@QMBCI) gave a wonderful insight into axi-cel in R/R #FollicularLymphoma at #ASH23 with an updated comparison of ZUMA-5 and SCHOLAR-5.
Watch here:
👉
#LYMsm #Lymphoma #NonHodgkinLymphoma #ImmunoOnc #HemOnc @ASH_hematology
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, comments on the updated 4-year ...
ow.ly
Popular videos
View all
Press Briefings
View all
Multiple Myeloma
View all
Lymphoma
View all
Acute Myeloid Leukemia
View all
Acute Lymphoblastic Leukemia
View all
Myelodysplastic Syndromes
View all
Chronic Lymphocytic Leukemia
View all
Myeloproliferative Neoplasms
View all
CAR-T & Cellular Therapy News
View all
